What Palatin Technologies (PTN) Said on Its Q4 Earnings CallDefense World · Sep 29, 2026
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call TranscriptSeeking Alpha · Sep 28, 2026
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdateGuruFocus · Sep 28, 2026
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePRNewsWire · Sep 28, 2026
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat ItNewsfile Corp · Aug 6, 2026Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 28, 2026 | -$1.20 | -$1.11 | Beat |
| May 13, 2026 | -$1.24 | -$0.37 | Beat |
| Feb 17, 2026 | -$2.35 | -$2.86 | Miss |
| Nov 14, 2025 | – | $4.26 | |
| Sep 23, 2025 | -$9.50 | -$3.43 | Beat |
| May 14, 2025 | -$8.50 | -$9.00 | Miss |